Top 5 Stocks to Buy Now
→ SpaceX is offering you shares. Don't take them. (From Behind the Markets) (Ad)tc pixel Free FDBK Stock Alerts

Feedback (FDBK) Competitors

Feedback logo
GBX 7.26 -0.04 (-0.55%)
As of 11:10 AM Eastern
Compare

FDBK vs. INHC, RENX, IQAI, DVRG, and SENS

Should you buy Feedback stock or one of its competitors? MarketBeat compares Feedback with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Feedback include Induction Healthcare Group (INHC), Renalytix (RENX), IQ-AI (IQAI), DeepVerge (DVRG), and Sensyne Health (SENS). These companies are all part of the "health information services" industry.

How does Feedback compare to Induction Healthcare Group?

Feedback (LON:FDBK) and Induction Healthcare Group (LON:INHC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Induction Healthcare Group has higher revenue and earnings than Feedback. Induction Healthcare Group is trading at a lower price-to-earnings ratio than Feedback, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Feedback£849.62K3.74-£10.84M-£15.74N/A
Induction Healthcare Group£12.57M0.72-£5.12M-£5.54N/A

In the previous week, Feedback's average media sentiment score of 0.00 equaled Induction Healthcare Group'saverage media sentiment score.

Company Overall Sentiment
Feedback Neutral
Induction Healthcare Group Neutral

Feedback has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, Induction Healthcare Group has a beta of -0.41, meaning that its share price is 141% less volatile than the broader market.

34.7% of Feedback shares are owned by institutional investors. Comparatively, 46.3% of Induction Healthcare Group shares are owned by institutional investors. 8.0% of Feedback shares are owned by company insiders. Comparatively, 54.6% of Induction Healthcare Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Induction Healthcare Group has a net margin of -23.86% compared to Feedback's net margin of -845.25%. Induction Healthcare Group's return on equity of -14.58% beat Feedback's return on equity.

Company Net Margins Return on Equity Return on Assets
Feedback-845.25% -135.17% -22.99%
Induction Healthcare Group -23.86%-14.58%-7.32%

Summary

Induction Healthcare Group beats Feedback on 8 of the 11 factors compared between the two stocks.

How does Feedback compare to Renalytix?

Renalytix (LON:RENX) and Feedback (LON:FDBK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Renalytix has a net margin of -680.00% compared to Feedback's net margin of -845.25%. Renalytix's return on equity of 274.67% beat Feedback's return on equity.

Company Net Margins Return on Equity Return on Assets
Renalytix-680.00% 274.67% -93.54%
Feedback -845.25%-135.17%-22.99%

14.0% of Renalytix shares are held by institutional investors. Comparatively, 34.7% of Feedback shares are held by institutional investors. 5.1% of Renalytix shares are held by insiders. Comparatively, 8.0% of Feedback shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Renalytix's average media sentiment score of 0.00 equaled Feedback'saverage media sentiment score.

Company Overall Sentiment
Renalytix Neutral
Feedback Neutral

Feedback has lower revenue, but higher earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Feedback, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Renalytix£3.30M2.48-£109.93M-£4.00N/A
Feedback£849.62K3.74-£10.84M-£15.74N/A

Renalytix has a beta of 1.808, suggesting that its share price is 81% more volatile than the broader market. Comparatively, Feedback has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Summary

Feedback beats Renalytix on 6 of the 11 factors compared between the two stocks.

How does Feedback compare to IQ-AI?

Feedback (LON:FDBK) and IQ-AI (LON:IQAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Feedback has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, IQ-AI has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market.

34.7% of Feedback shares are owned by institutional investors. 8.0% of Feedback shares are owned by company insiders. Comparatively, 66.0% of IQ-AI shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

IQ-AI has a net margin of -77.52% compared to Feedback's net margin of -845.25%. Feedback's return on equity of -135.17% beat IQ-AI's return on equity.

Company Net Margins Return on Equity Return on Assets
Feedback-845.25% -135.17% -22.99%
IQ-AI -77.52%-140.75%-22.03%

IQ-AI has lower revenue, but higher earnings than Feedback.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Feedback£849.62K3.74-£10.84M-£15.74N/A
IQ-AI£538.19K3.30N/AN/AN/A

In the previous week, Feedback's average media sentiment score of 0.00 equaled IQ-AI'saverage media sentiment score.

Company Overall Sentiment
Feedback Neutral
IQ-AI Neutral

Summary

Feedback beats IQ-AI on 5 of the 9 factors compared between the two stocks.

How does Feedback compare to DeepVerge?

Feedback (LON:FDBK) and DeepVerge (LON:DVRG) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

DeepVerge has a net margin of -19.81% compared to Feedback's net margin of -845.25%. DeepVerge's return on equity of -10.27% beat Feedback's return on equity.

Company Net Margins Return on Equity Return on Assets
Feedback-845.25% -135.17% -22.99%
DeepVerge -19.81%-10.27%-5.56%

In the previous week, Feedback's average media sentiment score of 0.00 equaled DeepVerge'saverage media sentiment score.

Company Overall Sentiment
Feedback Neutral
DeepVerge Neutral

Feedback has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, DeepVerge has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

DeepVerge has higher revenue and earnings than Feedback. Feedback is trading at a lower price-to-earnings ratio than DeepVerge, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Feedback£849.62K3.74-£10.84M-£15.74N/A
DeepVerge£12.41M0.00-£2.46M-£0.01N/A

34.7% of Feedback shares are held by institutional investors. Comparatively, 4.2% of DeepVerge shares are held by institutional investors. 8.0% of Feedback shares are held by insiders. Comparatively, 9.5% of DeepVerge shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

DeepVerge beats Feedback on 8 of the 10 factors compared between the two stocks.

How does Feedback compare to Sensyne Health?

Sensyne Health (LON:SENS) and Feedback (LON:FDBK) are both small-cap health information services industry companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

34.7% of Feedback shares are held by institutional investors. 8.0% of Feedback shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Sensyne Health has a net margin of 0.00% compared to Feedback's net margin of -845.25%. Sensyne Health's return on equity of 0.00% beat Feedback's return on equity.

Company Net Margins Return on Equity Return on Assets
Sensyne HealthN/A N/A N/A
Feedback -845.25%-135.17%-22.99%

In the previous week, Sensyne Health's average media sentiment score of 0.00 equaled Feedback'saverage media sentiment score.

Company Overall Sentiment
Sensyne Health Neutral
Feedback Neutral

Sensyne Health has higher revenue and earnings than Feedback. Feedback is trading at a lower price-to-earnings ratio than Sensyne Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sensyne Health£7.81M0.00N/A-£22.10N/A
Feedback£849.62K3.74-£10.84M-£15.74N/A

Summary

Sensyne Health beats Feedback on 5 of the 8 factors compared between the two stocks.

Get Feedback News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDBK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FDBK vs. The Competition

Export
MetricFeedbackHealth Information Services IndustryMedical SectorLON Exchange
Market Cap£3.18M£347.89M£6.45B£2.78B
Dividend Yield4.56%5.60%2.69%6.16%
P/E Ratio-0.46243.7021.07365.72
Price / Sales3.74132.06530.3686,253.69
Price / Cash1.1247.1444.8227.85
Price / Book0.137.3310.797.92
Net Income-£10.84M-£22.78M£3.56B£5.89B
7 Day Performance-2.22%-0.92%1.67%-0.87%
1 Month Performance-19.33%1.59%0.43%-0.76%
1 Year Performance-48.80%-10.58%32.84%70.67%

Feedback Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FDBK
Feedback
N/AGBX 7.26
-0.5%		N/A-51.6%£3.18M£849.62KN/A24
INHC
Induction Healthcare Group
N/AGBX 9.75
flat		N/A+0.0%£9.00M£12.57MN/A74
RENX
Renalytix
N/AGBX 1.87
-1.6%		N/A-74.2%£8.17M£3.30MN/A102
IQAI
IQ-AI
N/AGBX 0.80
flat		N/A+0.0%£1.77M£538.19KN/A6
DVRG
DeepVerge
N/AN/AN/AN/A£1.14M£12.41MN/A73

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:FDBK) was last updated on 6/23/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel